Need lower IOP?

Switch or Add

Consider a SWITCH to Rocklatan® to maximize IOP reduction with a single drop.¹,²

Why SWITCH to Rocklatan®?
- Superior IOP reduction vs latanoprost²
- 2 drugs, 1 drop, once a day helps lessen treatment burden, with 1 copay ¹³
- Mild, tolerable ocular side effects¹⁴
- No labeled contraindications¹

SWITCH to Rocklatan® for patients who:
- Need to maximize IOP reduction but don’t want to add another drop to regimen
- Prefer a simplified drop regimen
- Are burdened by multiple copays

Visit Rocklatan.com/hcp to learn more.

Consider ADDING Rhopressa® for additional IOP reduction when a PGA isn’t enough.⁵

Why ADD Rhopressa®?
- Consistent IOP reduction regardless of baseline⁵
- One drop, once a day⁵
- Tolerable ocular side effects⁶,⁷
- No labeled contraindications⁵

ADD Rhopressa® for patients who:
- Need additional IOP reduction and you prefer to add
- Cannot take a beta-blocker or alpha-agonist due to contraindications
- Cannot take a PGA or are PGA non-responders

Visit Rhopressa.com/hcp to learn more.

**IMPORTANT SAFETY INFORMATION**
**Contraindications**
None.

**Warnings and Precautions**
- Pigmentation changes
- Eyelash changes
- Intraocular inflammation
- Macular edema
- Herpetic keratitis
- Bacterial keratitis
- Contact lens wear

For full Rocklatan® Important Safety Information, see other side.

**INDICATIONS**
Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa® (netarsudil ophthalmic solution) 0.02% are approved for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
IMPORTANT SAFETY INFORMATION

Contraindications
None.

Warnings and Precautions
- Pigmentation changes
- Eyelash changes
- Intraocular inflammation
- Macular edema
- Herpetic keratitis
- Bacterial keratitis
- Contact lens wear

Adverse reactions
Rocklatan®: The most common ocular adverse reaction is conjunctival hyperemia (59%). Five percent of patients discontinued therapy due to conjunctival hyperemia. Other common ocular adverse reactions were: instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). Eye pruritus, visual acuity reduced, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5-8% of patients.

Netarsudil 0.02%: Instillation site discomfort, and blurred vision were reported in (11%). Eye pruritus, visual acuity reduced, increased lacrimation, (20%), corneal verticillata (15%), and conjunctival hemorrhage common ocular adverse reactions were: instillation site pain discontinued therapy due to conjunctival hyperemia. Other conjunctival hyperemia (59%). Five percent of patients and reduced visual acuity were reported in 5-10% of patients.

Staining, blurred vision, increased lacrimation, erythema of eyelid, and conjunctival hemorrhage. Instillation site erythema, corneal staining, increased lacrimation and erythema of eyelid.

Latanoprost 0.005%: Foreign body sensation, punctate keratitis, increased lacrimation and erythema of eyelid.

Adverse reactions (continued)

• Macular edema
• Intraocular inflammation
• Eyelash changes
• Bacterial keratitis

Please visit Rocklatan.com for full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATION
Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is approved for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of Rocklatan® should not exceed once daily. Rocklatan® may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

References

1. Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Prescribing Information, Aerie Pharmaceuticals, Inc., Irvine, Calif. 2019.
2. Asrani S, McKeel H, Scott B, et al. Pooled phase 3 efficacy analysis of a once-daily fixed-dose combination of netarsudil 0.02% and latanoprost 0.005% in ocular hypertension and open-angle glaucoma. Presented at the 13th Biennial Meeting of the European Glaucoma Society, March 2018.
5. Rhopressa® (netarsudil ophthalmic solution) 0.02% Prescribing Information, Aerie Pharmaceuticals, Inc., Irvine, Calif. 2019.